Press release
United Therapeutics Corporation Reports First Quarter 2022 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2022. Total revenue in the first quarter of 2022 grew 22% year-over-year to $461.9 million, compared to $379.1 million in the first quarter of 2021.\n\n“The hard work and dedication of our Unitherians has resulted in double-digit percentage revenue growth year-over-year for Tyvaso, Orenitram, Unituxin, and our total treprostinil portfolio, along with our second-highest revenue quarter ever,\" said Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics. “Likewise, our team is hard at work progressing our seven phase 3 studies that are now underway.”\n\n“We see continued traction for Tyvaso in pulmonary hypertension associated with interstitial lung disease, and we eagerly await the FDA’s decision on Tyvaso DPI later this month,” said Michael Benkowitz, President and Chief Operating Officer of United Therapeutics. “With this positive momentum, we continue to work toward reaching 6,000 patients on Tyvaso therapy by the end of 2022 and 25,000 patients on our therapies by the end of 2025.”\n\nFIRST QUARTER 2022 FINANCIAL RESULTS\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n \n\n\n\nThree Months Ended\nMarch 31,\n\n\n\n \n\n\n\nDollar\nChange\n\n\n\n \n\n\n\nPercentage\nChange\n\n\n\n\n\n \n\n\n\n2022\n\n\n\n \n\n\n\n2021\n\n\n\n \n\n\n\n \n\n\n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n \n\n\n\n\n\nRevenues\n\n\n\n$\n\n\n\n461.9\n\n\n\n \n\n\n\n$\n\n\n\n379.1\n\n\n\n \n\n\n\n$\n\n\n\n82.8\n\n\n\n \n\n\n\n22\n\n\n\n%\n\n\n\n\n\nNet income\n\n\n\n$\n\n\n\n239.9\n\n\n\n \n\n\n\n$\n\n\n\n28.3\n\n\n\n \n\n\n\n$\n\n\n\n211.6\n\n\n\n \n\n\n\n748\n\n\n\n%\n\n\n\n\n\nNet income, per basic share\n\n\n\n$\n\n\n\n5.31\n\n\n\n \n\n\n\n$\n\n\n\n0.63\n\n\n\n \n\n\n\n$\n\n\n\n4.68\n\n\n\n \n\n\n\n743\n\n\n\n%\n\n\n\n\n\nNet income, per diluted share\n\n\n\n$\n\n\n\n5.03\n\n\n\n \n\n\n\n$\n\n\n\n0.61\n\n\n\n \n\n\n\n$\n\n\n\n4.42\n\n\n\n \n\n\n\n725\n\n\n\n%\n\n\n\n\nRevenues\n\nThe table below summarizes the components of total revenues (dollars in millions):\n\n\n\n \n\n\n\nThree Months Ended\nMarch 31,\n\n\n\n \n\n\n\nDollar\nChan...